Team:Queens/Results

From 2009.igem.org

(Difference between revisions)
Line 123: Line 123:
<tr>
<tr>
<td align="left">
<td align="left">
-
<a name="Part2"><p style="font-size:150%;font-family:corbel;color:#172C4E;font-weight:bold">Part Two: Effector System</p></a>
+
<a name="Part2"><p style="font-size:150%;font-family:corbel;color:#172C4E;font-weight:bold">Part Two: Binding Construct</p></a>
<br/>
<br/>
<p style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
<p style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
-
Ideally, our effector system should only begin to produce the effectors once a threshold density of <i>E.coli</i> cells is reached at the plaque site. Since the system is in a prokaryotic chassis, signal transduction via the VLA-4/VCAM binding is not a realistic approach. Instead, we choose to employ the highly characterized LuxI/LuxR quorum sensing system in bacteria. Briefly, the effector proteins to be released at the site of plaque are placed under the control of pLux promoter, activated by a threshold concentration of AHL. AHL is constitutively produced by our cells and it will reach the threshold concentration once a sufficient amount of E.coli cells is bound to the plaque.
+
In our original design of the binding construct, constitutive promoter BBa_J23119 was used to control the expression of the chimeric protein receptor consisted of the Lpp-OmpA fusion, TEV protease cut sites and ITGA4 fragment. We ordered our construct to be synthesized by Mr. GENE in early June. However, Mr. GENE notified us in August that our construct appeared to be unstable in and toxic to <i>E. coli</i> cells. The reason might be that high expression level of Lpp-OmpA might interfere with bacterial physiology, causing severe growth inhibition and reduced viability. (Daugherty et al, 1999) Mr. Gene was able to give us a sequence-confirmed PCR product of the synthesized construct. Thus, we decided to replace P¬const with P¬tet (BBa_R0040) by PCR. Below is a schematic diagram of the construction process.  
</p>
</p>
<br/>
<br/>
-
<center><img src="https://static.igem.org/mediawiki/2009/5/55/QueensEffectors.jpg"></center>
+
<center><img src="https://static.igem.org/mediawiki/2009/0/08/QueensFigure2.png"></center>
<br/>
<br/>
<p style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
<p style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
-
In terms of treatment options we explored a number of routes; however, the following three proved to be the most feasible and advantageous choices. While we are not medical professionals and have not addressed the concept of dosage, the effectors we have chosen are such that mild overdoses would not be of great concern (i.e. beneficial effects far outweigh negative effects). We have also chosen these effectors for having minimal side effects.
+
<i>Fig. 2</i> Flowchart of PCR stitching for constructing the binding construct.  
</p>
</p>
<br/>
<br/>
<p style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
<p style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
-
<b>  1. Serum Amyloid A</b>
+
Due to time constraint, we were only able to confirm the stitching of Ptet-RBS fragment to Lpp-OmpA-Linker-TEVx2-Linker fragment (PCR round 2) using Agarose gel electrophoresis. The third round of PCR stitching did not yield expected band. Construction of the binding construct is ongoing. 
</p>
</p>
-
<p style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
+
<br/>
-
SAA converts cholesterol stored in plaques into a form more accessible by High Density Lipoprotein (HDL), which is the body’s natural mechanism for returning cholesterol to the liver for packaging, metabolism and/or excretion. It is our hope that this effector, when released specifically at the site of atherosclerosis, will induce plaque regression. 
+
<center><img src="https://static.igem.org/mediawiki/2009/1/14/QueensFigure3.png"></center>
-
</p>
+
-
<p style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
+
-
However, the clinical effectiveness of SAA is still in doubt for several reasons:
+
-
<pre style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
+
-
    * Not all atherosclerotic plaques are associated with cholesterol.
+
-
    * The body can naturally produce SAA at an astoundingly high rate, given the correct signals.
+
-
    * We are unsure if the molecule will reach the area of the plaque it is effective in.
+
-
    * We are unsure if the body produces enough HDL to clear atherosclerotic plaques.
+
-
</pre></p>
+
<br/>
<br/>
<p style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
<p style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
-
<b>   2. Heme Oxygenase 1 (HO-1)</b>
+
<i>Fig. 3</i> <i>In silico</i> model of the binding construct.
</p>
</p>
<p style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
<p style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
-
The HO-1 effector system involves the production of heme and HO-1. HO-1 catalyzes the degradation of heme into carbon monoxide (CO), biliverdin (BV), and free iron (Fe++), all of which have therapeutically beneficial effects on atherosclerotic plaques. CO acts as a local vasodilator, which may minimize chances of plaque rupture, as well as retard plaque growth. BV inhibits the proliferation of vascular smooth muscle cells, which has been shown to lead to stenosis of blood vessels. Fe++ induces the production of ferritin, which has an antioxidant effect that may protect the surrounding tissues from free radical attack and reduce the chance of plaque rupture. 
+
References:
-
</p>
+
<br/>
<br/>
-
<p style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
+
<br/>
-
<b>  3. Atrial Natriuretic Peptide (ANP)</b>
+
Daugherty, P.S., Olsen, M.J., Iverson, B.L. & Georgiou, G. (1999). Development of an optimized expression system for the screening of antibody libraries displayed on the <i>Escherichia coli</i> surface. <i>Protein Engineering.</i> Vol. 12, 7:613-621.
-
</p>
+
<br/>
-
<p style="border-style:none;background-color:#922334;font-size:120%;font-family:palatino linotype;color:#ECB528">
+
Yang, Z., Lui, Q., Wang, Q. & Zhang, Y. (2008). Novel bacterial surface display systems based on outer membrane anchoring elements from the marine bacterium <i>Vibrio anguillarum</i>. <i> American Society for Microbiology.</i> Vol. 74, 14: 4359-4365.
-
ANP activates membrane-bound guanylate cyclase (GCA), which increases the level of intracellular cGMP, a signalling molecule that mediates vasodilation. The effect of ANP is similar to that of carbon monoxide. cGMP also possess an anti-clotting effect, although it is unlikely that we can take advantage of this since platelets do not have membrane-bound guanylate cyclase.
+
</p>
</p>
<br/>
<br/>

Revision as of 00:25, 21 October 2009




Results


The following summarizes the results of the various aspects of this year's QGEM Project.


Part One: SAA

Part Two: Binding Construct

Part Three: Heme and HO-1

Part Four: Future Directions



Part One: SAA


Serum amyloid A (SAA) featured prominently on our list of possible effectors to release at the site of atherosclerotic plaques due to research done at Queen’s University by Tam et al. (2005). This research showed that treatment of SAA caused macrophages to reverse and prevent esterification of cholesterol, thereby allowing it to be exported out of plaques by high-density lipoprotein (HDL). In order to get the SAA to be picked up by the macrophages we needed to produce large quantities of the molecule, and then secrete it extracellularly. In order to secrete the protein we decided on using the twin-arginine translocase (TAT) system, which can transport fully folded proteins outside the cell (Sargent et al., 2006) and is found in the majority of prokaryotes. We then fused the TAT signal sequence to the front of our SAA sequence in order to produce a construct that should be able produce and secrete the protein, allowing it to be taken up by macrophages.



Fig. 1 SAA expression and secretion by E. coli cells. Cultures of E. coli cells containing either the SAA construct or control plasmid were spun down at 0, 4, and 12 hours after seeding. The culture medium and whole cell lysates were analyzed by SDS-PAGE and Western blot analysis with a polyclonal antibody recognizing whole SAA protein.


Our E. coli cells transformed with SAA construct did not appear to express or secrete SAA into the growth medium even after growing for 12 hours in optimum condition. This might be due to defective ligation of the Ptet-RBS fragment to the SAA-encoding gene. We plan to sequence the construct in the future.


References:

Benditt, E.P., Hoffman, J.S. & Eriksen, N. (1982). SAA, an apoprotein of HDL: its structure and function. New York Academy of Sciences. 82:183-189.
Ancsin, J.B. & Kisilevsky, R. (1999). The heparin/heparin sulfate-binding site on apo-serum amyloid A. Journal of Biological Chemistry. Vol. 274, 11:7172-7181.


Part Two: Binding Construct


In our original design of the binding construct, constitutive promoter BBa_J23119 was used to control the expression of the chimeric protein receptor consisted of the Lpp-OmpA fusion, TEV protease cut sites and ITGA4 fragment. We ordered our construct to be synthesized by Mr. GENE in early June. However, Mr. GENE notified us in August that our construct appeared to be unstable in and toxic to E. coli cells. The reason might be that high expression level of Lpp-OmpA might interfere with bacterial physiology, causing severe growth inhibition and reduced viability. (Daugherty et al, 1999) Mr. Gene was able to give us a sequence-confirmed PCR product of the synthesized construct. Thus, we decided to replace P¬const with P¬tet (BBa_R0040) by PCR. Below is a schematic diagram of the construction process.



Fig. 2 Flowchart of PCR stitching for constructing the binding construct.


Due to time constraint, we were only able to confirm the stitching of Ptet-RBS fragment to Lpp-OmpA-Linker-TEVx2-Linker fragment (PCR round 2) using Agarose gel electrophoresis. The third round of PCR stitching did not yield expected band. Construction of the binding construct is ongoing.



Fig. 3 In silico model of the binding construct.

References:

Daugherty, P.S., Olsen, M.J., Iverson, B.L. & Georgiou, G. (1999). Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface. Protein Engineering. Vol. 12, 7:613-621.
Yang, Z., Lui, Q., Wang, Q. & Zhang, Y. (2008). Novel bacterial surface display systems based on outer membrane anchoring elements from the marine bacterium Vibrio anguillarum. American Society for Microbiology. Vol. 74, 14: 4359-4365.


Part Three: Cleavage and Termination


After our chassis has been bound to the site of the plaque for a period of time, it should begin to produce DNases and proteases. The DNases will function to sheer the bacterial genome, making it unable to proliferate in the blood; this functions as a safe-guard against bacteremia. The proteases serve to detach the chassis from the plaque site, so as to avoid a build-up of dead cell debris in an already inflamed area.


Please note that Results are also available in PDF Format. 
Please click on the document you wish to view.

Laboratory One: Harry, Bogdan, James, Bryant

Laboratory Two: Kate, Mike






Last Updated: October 19, 2009 by Fr3P